# A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism

> **NCT03108833** · PHASE2 · COMPLETED · sponsor: **Tasly Biopharmaceuticals Co., Ltd.** · enrollment: 108 (actual)

## Conditions studied

- Acute Pulmonary Embolism

## Interventions

- **DRUG:** Recombinant Human Prourokinase
- **DRUG:** Alteplase

## Key facts

- **NCT ID:** NCT03108833
- **Lead sponsor:** Tasly Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-06
- **Primary completion:** 2019-12-19
- **Final completion:** 2019-12-19
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2021-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03108833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03108833, "A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03108833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*